<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04844619</url>
  </required_header>
  <id_info>
    <org_study_id>2021KYPJ080</org_study_id>
    <nct_id>NCT04844619</nct_id>
  </id_info>
  <brief_title>KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) Trial</brief_title>
  <acronym>KDR-NVG</acronym>
  <official_title>Evaluation of Effectiveness of KDR2-2 Suspension Eyedrop on Neovascular Regression in the Treatment of Neovascular Glaucoma: an Exploratory Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical trial is aimed to evaluate the anti-neovascular effect of KDR2-2 suspension&#xD;
      eyedrop in the treatment of neovascular glaucoma. Fourty subjects would receive either 0.96&#xD;
      or 3.84 mg/per day/eye, in a QID fashion, ×7 days (those without complications can continue&#xD;
      to 28 days). The anti-neovascular effect of KDR2-2 on iris neovascularization would be&#xD;
      evaluated at day 1, day 7, day 14, day 28 after KDR2-2 usage.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neovascular glaucoma (NVG) has a high blinding rate and poor prognosis. Anti-glaucoma surgery&#xD;
      is the main stake of saving visual function and relieving pain, but the proliferation of iris&#xD;
      neovascularization (NVI) makes it difficult to treat NVG. Normally, the patients need an&#xD;
      intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) agents prior to&#xD;
      glaucoma surgery to control the NVI proliferation.&#xD;
&#xD;
      KDR2-2, a novel small-molecule tyrosine kinase inhibitor targeting VEGF receptor 2 (VEGFR2),&#xD;
      has demonstrated anti-neovascular effect without obvious side-effects or complications in&#xD;
      animal studies and a Phase I clinical trial (NCT04620109). In this study, 40 patients with&#xD;
      NVG will be included to evaluate the effectiveness of KDR2-2 suspension eyedrop on NVI in NVG&#xD;
      eyes. The included subjects would receive either 0.96 or 3.84 mg/day/eye, in a QID fashion,&#xD;
      ×7 days (those without complications can continue to 28 days).&#xD;
&#xD;
      This study aims to and propose a novel, non-invasive and more compliant method for the&#xD;
      treatment of NVG.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 19, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of iris neovascularization</measure>
    <time_frame>Day 0, 7, 14, 21 and 28</time_frame>
    <description>Changes of the iris neovascularization using anterior photography or anterior optical coherence tomography angiography.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>Day 0, 1, 7, 14, 21 and 28</time_frame>
    <description>Measurement of intraocular pressure using non-contact tonometer or iCare tonometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best-corrected visual acuity</measure>
    <time_frame>Day 0, 1, 7, 14, 21 and 28</time_frame>
    <description>Measurement of best-corrected visual acuity with Snellen LogMAR Chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal endothelium count</measure>
    <time_frame>Day 0, 7 and 28</time_frame>
    <description>Corneal endothelium count using endokeratoscope</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Day 0, 1, 7, 14, 21 and 28</time_frame>
    <description>Adverse events related with the anti-angiogenic effect of KDR2-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of anterior chamber structures</measure>
    <time_frame>Day 0, 7, 14, 21 and 28</time_frame>
    <description>Changes of anterior chamber using anterior segment optical coherence tomography.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Neovascular Glaucoma</condition>
  <condition>Neovascularization</condition>
  <arm_group>
    <arm_group_label>4mg/ml KDR2-2 group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients with NVG will receive 4.0 mg/ml KDR2-2 suspension eyedrop and the anti-neovascular effect of KDR2-2 would be evaluated during the follow-up visits.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>16mg/ml KDR2-2 group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients with NVG will receive 16mg/ml KDR2-2 suspension eyedrop and the anti-neovascular effect of KDR2-2 would be evaluated during the follow-up visits.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4mg/ml KDR2-2 suspension eyedrop</intervention_name>
    <description>KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).&#xD;
KDR2-2 suspension eyedrop is developed for the treatment of iris neovascularization.</description>
    <arm_group_label>4mg/ml KDR2-2 group</arm_group_label>
    <other_name>Low-dose KDR2-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>16mg/ml KDR2-2 suspension eyedrop</intervention_name>
    <description>KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).&#xD;
KDR2-2 suspension eyedrop is developed for the treatment of iris neovascularization.</description>
    <arm_group_label>16mg/ml KDR2-2 group</arm_group_label>
    <other_name>High-dose KDR2-2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-75;&#xD;
&#xD;
          -  The best-corrected visual acuity (BCVA) of the included eyes was &lt;0.01 (Snellen&#xD;
             chart);&#xD;
&#xD;
          -  The BCVA of the contralateral eye of the included subjects was &gt;0.1;&#xD;
&#xD;
          -  Patients with clinically diagnosed neovascular glaucoma; The diagnostic criteria for&#xD;
             neovascularization glaucoma were as follows: Intraocular pressure &gt; 21mmHg measured by&#xD;
             Goldmann applanation tonometer; Neovascularization is seen in the iris or anterior&#xD;
             chamber angle, with or without corneal edema;&#xD;
&#xD;
          -  Compliance with follow up for more than 28 days and written informed consent obtained;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intravitreal injection of anti-VEGF drugs within 3 month before enrollment;&#xD;
&#xD;
          -  Participation in other clinical trials within 1 month;&#xD;
&#xD;
          -  Suffering from other ocular diseases that affect ocular examinations (e.g.&#xD;
             keratopathy, uveitis, intraocular infection, etc.);&#xD;
&#xD;
          -  Those who plan to receive ocular surgery during the follow-up period;&#xD;
&#xD;
          -  Premenopausal women without birth control;&#xD;
&#xD;
          -  Having other systemic diseases such as severe liver and kidney function damage,&#xD;
             cardiovascular disorders, respiratory disorders, etc.) that may affect the&#xD;
             anti-neovascular effect of KDR2-2 or more likely to develop adverse events ;&#xD;
&#xD;
          -  Systemic infections under treatment;&#xD;
&#xD;
          -  Any study in which the physician believes that the patient's condition will interfere&#xD;
             with the clinical trial (e.g., the patient is prone to stress, mood disorders,&#xD;
             depression, etc.);&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiulan Zhang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongshan Ophthalmic Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiulan Zhang, MD, PhD</last_name>
    <phone>+862066610720</phone>
    <email>zhangxl2@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Ophthalmic Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>51000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiulan Zhang, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 13, 2021</study_first_submitted>
  <study_first_submitted_qc>April 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2021</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Xiulan Zhang</investigator_full_name>
    <investigator_title>Professor of Ophthalmology, Director of Clinical Research Center, Director of CFDA-certified Pharmaceutical Research Unit, State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center</investigator_title>
  </responsible_party>
  <keyword>Neovascular Glaucoma</keyword>
  <keyword>Neovascularization</keyword>
  <keyword>anti-VEGF</keyword>
  <keyword>vascular endothelial growth factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Neovascular</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

